[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]



September 20, 2017

FDA Approval of TisagenlecleucelPromise and Complexities of a $475 000 Cancer Drug

Abstract Full Text
free access
JAMA. Published online September 20, 2017. doi:10.1001/jama.2017.15218

This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing.